OPEN END TURBO PUT WARRANT - ASTRAZENECA ADR | Market Closed - Börse Stuttgart 12:17:03 03/07/2024 pm IST | ||
| 2.02 EUR | +1.00% |
|
| Current month | +5.76% | ||
| 1 month | +8.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 2.02 | +1.00% |
| 02/24/02 | 2 | +5.26% |
| 01/24/01 | 1.9 | -0.52% |
| 28/24/28 | 1.91 | +2.14% |
| 27/24/27 | 1.87 | +9.36% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 12:17 pm IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | UBS |
| WKN | UM5ZZ0 |
| ISIN | DE000UM5ZZ03 |
| Date issued | 30/05/2024 |
| Strike | 98.22 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.03 € |
|---|---|
| Lowest since issue | 1.64 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
153.4
USD
Average target price
174.6
USD
Spread / Average Target
+13.78%
- Stock Market
- Certificates
- Certificat
